Facultad de Ciencias del Mar y Recursos Biológicos

URI permanente para esta comunidad

http://repositorioabierto.uantof.cl/handle/uantof/3

Examinar

Examinando Facultad de Ciencias del Mar y Recursos Biológicos por Autor "Angello Retamal Díaz"

Mostrando 1 - 2 de 2
  • Miniatura
    Ítem
    Inactivated Vaccine-Induced SARS-CoV-2 Variant-SpecificImmunity in Children
    (2022) Jorge A. Soto; Felipe Melo González; Cristián Gutierrez Vera; Bárbara M. Schultz; Roslye V. Berríos Rojas; Daniela Rivera Pérez; Alejandro Piña Iturbe; Guillermo Hoppe Elsholz; Luisa F. Duarte; Yaneisi Vázquez; Daniela Moreno Tapia; Mariana Ríos; Pablo A. Palacios; Richard Garcia Betancourt; Álvaro Santibañez; Gaspar A. Pacheco; Constanza Mendez; Catalina A. Andrade; Pedro H. Silva; Benjamín Diethelm Varela; Patricia Astudillo; Mario Calvo; Antonio Cárdenas; Marcela González; Macarena Goldsack; Valentina Gutiérrez; Marcela Potin; Andrea Schilling; Lorena I. Tapia; Loreto Twele; Rodolfo Villena; Alba Grifoni; Alessandro Sette; Daniela Weiskopf; Rodrigo A. Fasce; Jorge Fernández; Judith Mora; Eugenio Ramírez; Aracelly Gaete Argel; Mónica L. Acevedo; Fernando Valiente Echeverría; Ricardo Soto Rifo; Angello Retamal Díaz; Nathalia Muñoz Jofré; PedCoronaVac03CL Study Group; Xing Meng; Qianqian Xin; Eduardo Alarcón Bustamante; José V. González Aramundiz; Nicole Le Corre; María Javiera Álvarez Figueroa; Pablo A. González; Katia Abarca; Cecilia Perret; Leandro J. Carreño; Susan M. Bueno; Alexis M. Kalergis
    Multiple vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been evaluated in clinical trials. However, trials addressing the immune response in the pediatric population are scarce. The inactivated vaccine CoronaVac has been shown to be safe and immunogenic in a phase 1/2 clinical trial in a pediatric cohort in China. Here, we report interim safety and immunogenicity results of a phase 3 clinical trial for CoronaVac in healthy children and adolescents in Chile. Participants 3 to 17 years old received two doses of CoronaVac in a 4-week interval until 31 December 2021. Local and systemic adverse reactions were registered for volunteers who received one or two doses of CoronaVac. Whole-blood samples were collected from a subgroup of 148 participants for humoral and cellular immunity analyses. The main adverse reaction reported after the first and second doses was pain at the injection site. Four weeks after the second dose, an increase in neutralizing antibody titer was observed in subjects relative to their baseline visit. Similar results were found for activation of specific CD41 T cells. Neutralizing antibodies were identified against the Delta and Omicron variants. However, these titers were lower than those for the D614G strain. Importantly, comparable CD41 T cell responses were detected against these variants of concern. Therefore, CoronaVac is safe and immunogenic in subjects 3 to 17 years old, inducing neutralizing antibody secretion and activating CD41 T cells against SARS-CoV-2 and its variants. (This study has been registered at ClinicalTrials .gov under no. NCT04992260.)
  • Miniatura
    Ítem
    New insights into the pathogenesis of SARS-CoV-2 during and after the COVID- 19 pandemic
    (2024) Jonatan J. Carvajal; Valeria García Castillo; Shelsy V. Cuellar; Claudia P. Campillay Véliz; Camila Salazar Ardiles; Andrea M. Avellaneda; Christian A. Muñoz; Angello Retamal Díaz; Susan M. Bueno; Pablo A. González; Alexis M. Kalergis; Margarita K. Lay
    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the respiratory distress condition known as COVID-19. This disease broadly affects several physiological systems, including the gastrointestinal, renal, and central nervous (CNS) systems, significantly influencing the patient’s overall quality of life. Additionally, numerous risk factors have been suggested, including gender, body weight, age, metabolic status, renal health, preexisting cardiomyopathies, and inflammatory conditions. Despite advances in understanding the genome and pathophysiological ramifications of COVID-19, its precise origins remain elusive. SARS-CoV-2 interacts with a receptor-binding domain within angiotensin-converting enzyme 2 (ACE2). This receptor is expressed in various organs of different species, including humans, with different abundance. Although COVID-19 has multiorgan manifestations, the main pathologies occur in the lung, including pulmonary fibrosis, respiratory failure, pulmonary embolism, and secondary bacterial pneumonia. In the post- COVID-19 period, different sequelae may occur, which may have various causes, including the direct action of the virus, alteration of the immune response, and metabolic alterations during infection, among others. Recognizing the serious adverse health effects associated with COVID-19, it becomes imperative to comprehensively elucidate and discuss the existing evidence surrounding this viral infection, including those related to the pathophysiological effects of the disease and the subsequent consequences. This review aims to contribute to a comprehensive understanding of the impact of COVID-19 and its long-term effects on human health.